Another drug may join list of FDA-authorized COVID treatments https://www.usatoday.com/story/news/health/2021/05/28/covid-memorial-day-cvs-vaccine-variant-mask-cdc/7477992002/ Biopharmaceutical company Humanigen submitted their drug Lenzilumab to the Food and Drug Administration for emergency use authorization to treat hospitalized patients with COVID-19, the company announced Friday. If authorized, the drug will join a growing list of treatments authorized by the FDA for COVID-19. Lenzilumab focuses on preventing and treating an overactive immune response commonly known as a “cytokine storm,” which causes the immune system to kill both healthy and diseased tissue. In a Phase 3 study, the drug improved the likelihood of survival without ventilation by 54% in newly hospitalized patients. Survival improved by 92% in patients who also took certain steroids and remdesivir. “There is a need for hospitalized patients who require supplementary oxygen,” said Dr. Cameron Durrant, Humanigen’s chief executive officer. “Treatments can be lifesaving; despite vaccinations, infections and significant breakthrough disease will continue.” “There is a need for hospitalized patients who require supplementary oxygen,” said Dr. Cameron Durrant, Humanigen’s chief executive officer. “Treatments can be lifesaving; despite vaccinations, infections and significant breakthrough disease will continue.”